MARKET

MBIO

MBIO

Mustang Bio
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.7381
+0.0072
+0.99%
After Hours: 0.7400 +0.0019 +0.26% 19:00 08/11 EDT
OPEN
0.7500
PREV CLOSE
0.7309
HIGH
0.7945
LOW
0.7200
VOLUME
594.50K
TURNOVER
0
52 WEEK HIGH
3.090
52 WEEK LOW
0.5100
MARKET CAP
76.06M
P/E (TTM)
-0.9579
1D
5D
1M
3M
1Y
5Y
Mustang Bio GAAP EPS of -$0.19 beats by $0.02
Mustang Bio press release (<span class="ticker-h...
Seekingalpha · 10h ago
BRIEF-Mustang Bio Reports Second Quarter 2022 Financial Results And Recent Corporate Highlights
BRIEF-Mustang Bio Reports Second Quarter 2022 Financial Results And Recent Corporate Highlights
Reuters · 11h ago
Mustang Bio Announces First Patient Successfully Treated By Ex Vivo Lentiviral Gene Therapy To Treat RAG1 Severe Combined Immunodeficiency
Mustang Bio, Inc. (“Mustang”) (NASDAQ:MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for
Benzinga · 07/27 12:14
Mustang Bio, Inc. (NASDAQ:MBIO) insider upped their holding by 9.9% earlier this year
From what we can see, insiders were net buyers in Mustang Bio, Inc.'s ( NASDAQ:MBIO ) during the past 12 months. That...
Simply Wall St. · 07/17 12:21
B. Riley Securities Trims Mustang Bio's Price Target to $4 from $5, Keeps Buy Rating
MT Newswires · 07/14 09:55
BRIEF-Mustang Bio Inc Says U.S. FDA Has Granted Orphan Drug Designation To MB-106
reuters.com · 06/22 13:23
Mustang Bio CAR T cell therapy for rare blood cancer gets FDA orphan drug status
The U.S. Food and Drug Administration (FDA) granted orphan drug designation to Mustang Bio's (NASDAQ:MBIO) CAR T cell therapy MB-106 to treat Waldenstrom macroglobulinemia (WM). WM is rare cancer that begins when the
Seekingalpha · 06/22 13:22
Mustang Bio Shares Gain As FDA Grants Orphan Drug Status To Waldenstrom Drug
The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Mustang Bio’s (NASDAQ: MBIO) lead drug MB-106 for the treatment of Waldenstrom macroglobulinemia (WM), a rare type of B-cell non-Hodgkin lymphoma (B-NHL).
Benzinga · 06/22 12:53
More
No Data
Learn about the latest financial forecast of MBIO. Analyze the recent business situations of Mustang Bio through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

40.00%Strong Buy
60.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average MBIO stock price target is 7.00 with a high estimate of 8.00 and a low estimate of 4.000.
High8.00
Average7.00
Low4.000
Current 0.7381
EPS
Actual
Estimate
-0.18-0.13-0.09-0.04
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 112
Institutional Holdings: 29.81M
% Owned: 28.93%
Shares Outstanding: 103.05M
TypeInstitutionsShares
Increased
13
1.66M
New
10
189.94K
Decreased
34
4.06M
Sold Out
13
458.18K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.11%
Pharmaceuticals & Medical Research
-1.16%
Key Executives
Chairman/Executive Director
Michael Weiss
President/Chief Executive Officer/Director
Manuel Litchman
Chief Financial Officer
Eliot Lurier
Director
Lindsay Rosenwald
Independent Director
Adam Chill
Independent Director
Neil Herskowitz
Independent Director
Michael Zelefsky
No Data
No Data
About MBIO
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company that is focused on translating medical breakthroughs in cell and gene therapies into cures for hematologic cancers, solid tumors and rare genetic diseases. The Company's pipeline is focused on three core areas: gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies and CAR T therapies for solid tumors. Its products include MB-107 and MB-207 is an Ex vivo Lentiviral Therapy for X-linked Severe Combined Immunodeficiency (XSCID). XSCID is a rare genetic immune system condition also known as bubble boy disease. It is developing CAR T therapies for hematologic malignancies in partnership with COH targeting CD123 (MB-102) and CS1 (MB-104) and with Fred Hutch targeting CD20 (MB-106). The Company is also developing CAR T therapies for solid tumors in partnership with COH targeting IL13Ra2 (MB-101), HER2 (MB-103) and PSCA (MB-105).

Webull offers kinds of Mustang Bio Inc stock information, including NASDAQ:MBIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MBIO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MBIO stock methods without spending real money on the virtual paper trading platform.